Clarity AD open-label extension data do not robustly confirm disease course modification by lecanemab in ApoE4 heterozygotes and non-carriers

The Journal of Prevention of Alzheimer s Disease 2026 Open access

Read full text

Authors: Jemma Hazan, Kathy Y. Liu, Robert Howard

DOI: 10.1016/j.tjpad.2026.100587

Cited by: 1

References: 2

Fields of Study & Subjects

Bioinformatics and Genomic Networks Computational Drug Discovery Methods HER2/EGFR in Cancer Research

References 2